Warner Chilcott Evaluating Possible Sale

Warner Chilcott is evaluating options, including a possible sale of the company, after receiving interest from strategic and private-equity buyers, Reuters reported Monday, citing Bloomberg News. Goldman Sachs is helping the Nasdaq-listed drugmaker assess interest, said the news service, citing people with knowledge of the matter.

(Reuters) – Warner Chilcott is evaluating options, including a possible sale of the company, after receiving interest from strategic and private-equity buyers, Bloomberg News reported on Monday.

 

Goldman Sachs is helping the Nasdaq-listed drugmaker assess interest, said the news service, citing people with knowledge of the matter. Warner Chilcott is also considering paying a dividend as an alternative to a sale, one person said.

 

Warner Chilcott’s stock rose 8 percent to $18.79 on Friday on takeover speculation, giving it a market capitalization of $4.7 billion, after the Times of London said in a market report there was talk Bayer might bid $32 a share.

 

Reuters reported on April 25 that Bayer was nearing a multibillion-dollar acquisition to bolster its healthcare division, citing three people close to the planned transaction.

 

Warner Chilcott focuses on women’s health care, dermatology, urology and gastroenterology.

 

(Reporting by Ben Hirschler)